Acute Myeloid Leukemia

Podcasts

Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML

12/15/2018

Pamela S. Becker, MD, PhD, discussed the clinical significance and potential implications of a study examining the use of Use of gemtuzumab ozogamicin in patients with relapsed or refractory AML.

Pamela S. Becker, MD, PhD,...

12/15/2018

Oncology

Crenolanib–Chemo Combo Improves Outcomes in Newly Diagnosed, FLT3-Mutated AML

12/11/2018

A combination therapy including crenolanib improved outcomes in patients with newly diagnosed AML positive for FLT3 and other co-occurring driver mutations.

A combination therapy including...

12/11/2018

Oncology

Targeted Therapy Promising for Certain Patients With Relapsed/Refractory AML

12/06/2018

Gemtuzumab ozogamicin is safe for patients with AML, but combinations of the drug may be better suited for certain patients with relapsed or refractory disease.

Gemtuzumab ozogamicin is safe...

12/06/2018

Oncology

AML Outcomes With Decitabine Not Dependent on Dosing Schedule

12/02/2018

Older patients with newly diagnosed AML had similar outcomes regardless of whether they received decitabine in a 5- or 10-day schedule, a recent study has shown.

Older patients with newly...

12/02/2018

Oncology

Podcasts

Gail J. Roboz, MD, Discusses Treatment Options for Patients With AML

11/01/2018

In this 3-part podcast series, Dr Roboz discusses the current available therapy options for patients with AML, expanding upon data she presented at the 2018 ASH Meeting on Hematologic Malignancies.

In this 3-part podcast series,...

11/01/2018

Oncology